knowledge
You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences. Sign up to get it delivered in your inbox every Tuesday and Thursday.
Diabetes: Better shows data on app’s benefit with GLP-1s
advertisement
Better Therapeutics announced top-line data suggesting that its prescription app for diabetes treatment, AspyreRx, can boost the impact of GLP-1 diabetes treatments. According to the release, a subgroup analysis of 160 participants in its pivotal trial on GLP-1 treatment found that the behavior modification app produced statistically significant reductions in A1C compared to a control group.
Get unlimited access to award-winning journalism and exclusive events.
Subscribe Log In
Previous article：
Why scientists need input from humanists on sensitive research
Next article： Heart attack and stroke risk calculators need revising
Next article： Heart attack and stroke risk calculators need revising
